MEI Pharma Commits $100M to Litecoin Treasury with Charlie Lee on Board

Highlights:

• MEI Pharma has committed to a Litecoin Treasury plan of $100 million.
• Litecoin Foundation and Charlie Lee are supporting the project.
• The stock of MEI Pharma soared following the treasury announcement.

MEI Pharma has stepped into the crypto industry with a Litecoin Treasury strategy of $100 million. The biotech company listed on the Nasdaq has partnered with Titan Partners Group and GSR to undertake the private placement. As stated in the press release, Charlie Lee, the founder of Litecoin, has officially joined the Board of Directors of MEI Pharma. This move makes the collaboration more solid and affirms the company’s path. The Litecoin Foundation has gone further to invest in MEI Pharma, which strengthens the long-term partnership.

Litecoin has established a reputation for being fast and secure with low-cost transactions. It has resulted in real-world payments on platforms such as BitPay. Thus, MEI Pharma has selected this reliability to reinforce its treasury strategy. The company believes that this shift will assist in effective capital flow in the international markets.

I'm excited to see $100M invested into a Litecoin treasury company!

I will be advising and joining the board of directors of MEIP. @LTCFoundation and I will also work closely with @GSR_io and @MEI_Pharma to contribute to the Litecoin ecosystem. Exciting times for Litecoin! https://t.co/nitDbOHPa4

— Charlie Lee Ⓜ️🕸️ (@SatoshiLite) July 18, 2025

Why Litecoin Over Other Cryptos

Unlike Bitcoin, Litecoin is focused on speed and low fees as opposed to being a macro hedge. Ethereum has an advantage in that area with its smart contract platform, yet Litecoin has an advantage in everyday payments. In the case of MEI Pharma, it is utility and not speculative value.

Litecoin has been able to provide a secure transaction at minimal costs. This makes it suitable for cross-border operations and retail integration. Institutional support is expected to increase with Lee being an advisor to MEI Pharma. Moreover, the collaboration represents a first-of-its-kind crossover between the biotech and blockchain industries.

Charlie Lee has been a prominent player in the crypto sector since the inception of Litecoin in 2011. His participation in the activation of SegWit and in supporting Lightning Network contributed to the development of both Litecoin and Bitcoin. His appointment to the board of MEI Pharma is an indication that he is committed to integrating crypto.

This investment by the Litecoin Foundation shows the mission of the organization to boost adoption. This direct relationship will be advantageous to MEI Pharma and also facilitate the expansion of Litecoin in the traditional finance industries.

Litecoin Treasury Strategy Gains Momentum

The Litecoin Treasury plan makes MEI Pharma one of the initial publicly traded biotech companies to adopt this plan. The business has undertaken an analysis of business options prior to the selection of the option. This decision is supported by the partnership with GSR and the Litecoin Foundation.

Treasury strategies are drawing attention from both crypto and traditional finance. Other firms, such as Thumzup Media, have also expressed interest in holding Litecoin. But the initiative of MEI Pharma is especially noteworthy in terms of its magnitude and implementation plan. After the announcement, MEI Pharma stock rose by over 50% during the pre-market trading. The price extended its upward trend, extending the gains made earlier in the week. Meanwhile, Litecoin also experienced a price rally, reaching $105 and approaching a weekly peak.